Answers are grounded in this paper and cite their sources.
The cellular origin, clinical significance, and metabolic features of the senescence-associated secretory phenotype (SASP) in prostate cancer remain poorly resolved. We integrated bulk transcriptomes from TCGA-PRAD (primary, n = 495) and SU2C (mCRPC, n = 208), two single-cell RNA-sequencing datasets, seven Visium sections, and one Xenium prostate adenocarcinoma section, together with immunoblotting in LNCaP and castration-adapted C4-2 cells treated with charcoal-stripped serum (CSS), enzalutamide (ENZ), and dihydrotestosterone (DHT). SASP formed a smooth, continuous gradient across bulk tumors rather than discrete subtypes. In Xenium, 4,657 of 25,517 tumor cells (18.3%) were positive for a senescence surrogate driven predominantly by p21 (CDKN1A) transcript detection; the local fraction of these cells correlated with a bin-level matrix-remodeling SASP program and glycolysis, but not with inflammatory SASP. The single-cell atlas revealed expansion of AR-low, stasis/senescence-like states in advanced disease. Within the adenocarcinoma compartment of one CRPC section, senescence-like hotspots showed higher glycolysis scores without a concomitant rise in proliferation. In vitro, CSS and ENZ increased p21/p16 and glycolytic proteins (GLUT1, LDHA, HK2), and treatment with 2-deoxy-D-glucose (2-DG) or the LDHA inhibitor FX-11 was associated with lower p21/p16 abundance. Androgen deprivation is associated with a prostate cancer senescence-like state and a glycolysis-related program; LDHA is a candidate metabolic node for further investigation; the present data do not establish therapeutic selectivity or efficacy. These spatial associations do not establish the cellular source of the SASP-related transcripts or paracrine signaling.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: